Table 7.
Incidence of lung cancer. Events after 2 versus 5 years of tamoxifen treatment. a
| Years after surgery | TAM 2 yrs (n = 2091) |
TAM 5yrs (n = 2009) |
HR 5 vs 2 yrs |
95% CI | SHR 5 vs 2 yrs |
95% CI |
|---|---|---|---|---|---|---|
| Number of events | ||||||
| ≥2 | 46 | 25 | 0.51 | 0.32–0.84 | 0.58 | 0.35–0.97 |
| 2–5 | 6 | 2 | 0.34 | 0.07–1.69 | 0.25 | – |
| 5–15 | 23 | 6 | 0.24 | 0.10–0.59 | 0.28 | 0.11–0.70 |
| 15 – | 17 | 17 | 0.95 | 0.49–1.87 | 0.91 | 0.46–1.80 |
CI = confidence interval; HR = hazard ratio; SHR = subhazard ratio; TAM = tamoxifen.
a
Before the randomization, 22 patients were diagnosed with contralateral breast cancer and 1 patient in each treatment group were diagnosed with lung cancer. These patients were excluded in this analysis.